Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Q Chip (United Kingdom) a preclinical-stage biopharmaceutical company focused on sustained release formulations of oncology and endocrine therapeutics, closed a $6M Series C financing. Participants include Limburg Ventures and Nedermaas Hightech Ventures.

Versartis (Mountain View, CA) a clinical-stage biopharma company focused on growth hormone deficiency and additional endocrine disorders, closed a $21M Series B financing. Participants include Advent Venture Partners, Index Ventures and Amunix.

Syntaxin (United Kingdom) a preclinical-stage biopharmaceutical company focusing on targeted secretion inhibitors for the potential treatment of pain, endocrine disease and cancer, closed a $28.3M Series C financing. Participants include Lundbeckfond Ventures, Ipsen, Seventure Partners, Abingworth, SROne, Life Science Partners, Johnson & Johnson Development Corp and Quest for Growth.

Aragon Pharmaceuticals (San Diego, CA) a preclinical-stage stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer, closed a $22M Series B financing. Participants include Aisling Capital, OrbiMed and The Column Group.

Versartis (Redwood City, CA) a preclinical-stage large molecule company focused on diabetes and growth hormone deficiency, closed an $11M Series A financing. Participants include Index Ventures.

Dicerna Pharmaceuticals (Watertown, MA) clinical-stage biopharmaceutical company developing RNAi therapeutics for multiple clinical applications, closed a $8.4M Series A. Participants include Abingworth, Oxford Bioscience Partners and Skyline Ventures.

  

to top of page...